Ignacio Ivan Wistuba
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- Cancer Research top 0.02%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 286
- Cancer Immunotherapy and Biomarkers 85
- Lung Cancer Research Studies 61
- Cancer Cells and Metastasis 37
- Cancer Research 180
- Cancer Genomics and Diagnostics 123
- Co-authors
- Adi F. Gazdar (83 shared papers)John Dorrance Minna (95 shared papers)Carmen Behrens (137 shared papers)Fred R. Hirsch (11 shared papers)Keith M. Kerr (7 shared papers)Ming‐Sound Tsao (8 shared papers)Ximing Tang (45 shared papers)Jaime Rodriguez‐Canales (49 shared papers)
- Journals
- Journal of Thoracic Oncology (84 papers)Clinical Cancer Research (70 papers)Cancer Research (42 papers)Annals of Oncology (17 papers)Nature Communications (16 papers)
- Partner nations
- United StatesNetherlandsJapan
In The Last Decade
Ignacio Ivan Wistuba
793 papers receiving 80.7k citations
Ignacio Ivan Wistuba's Hit Papers
Peers
Comparison fields: 5 of 189
- Oncology 31.2k
- Cancer Research 16.6k
- Pulmonary and Respiratory Medicine 27.3k
- Immunology 8.7k
- Molecular Biology 27.4k
Countries citing papers authored by Ignacio Ivan Wistuba
This map shows the geographic impact of Ignacio Ivan Wistuba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ignacio Ivan Wistuba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ignacio Ivan Wistuba more than expected).
Fields of papers citing papers by Ignacio Ivan Wistuba
This network shows the impact of papers produced by Ignacio Ivan Wistuba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ignacio Ivan Wistuba. The network helps show where Ignacio Ivan Wistuba may publish in the future.
Co-authors
The 25 scholars most cited alongside Ignacio Ivan Wistuba, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 803 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma Hit paper breakdown → | 2011 | 3910 |
| 2 | The 2015 World Health Organization Classification of Lung Tumors Hit paper breakdown → | 2015 | 3510 |
| 3 | Somatic mutations affect key pathways in lung adenocarcinoma Hit paper breakdown → | 2008 | 2237 |
| 4 | Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation Hit paper breakdown → | 2018 | 1617 |
| 5 | Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs Hit paper breakdown → | 2014 | 1428 |
| 6 | STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma Hit paper breakdown → | 2018 | 1296 |
| 7 | PD-L1 as a biomarker of response to immune-checkpoint inhibitors Hit paper breakdown → | 2021 | 1175 |
| 8 | Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial Hit paper breakdown → | 2017 | 1128 |
| 9 | Characterizing the cancer genome in lung adenocarcinoma Hit paper breakdown → | 2007 | 924 |
| 10 | An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance Hit paper breakdown → | 2012 | 850 |
| 11 | Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression Hit paper breakdown → | 2014 | 834 |
| 12 | Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade Hit paper breakdown → | 2016 | 817 |
| 13 | Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing Hit paper breakdown → | 2014 | 796 |
| 14 | Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities Hit paper breakdown → | 2015 | 770 |
| 15 | Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer Hit paper breakdown → | 2019 | 715 |
| 16 | Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities Hit paper breakdown → | 2021 | 708 |
| 17 | The BATTLE Trial: Personalizing Therapy for Lung Cancer Hit paper breakdown → | 2011 | 702 |
| 18 | Epidemiology and Molecular Pathology of Gallbladder Cancer Hit paper breakdown → | 2001 | 701 |
| 19 | A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer Hit paper breakdown → | 2017 | 663 |
| 20 | Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial Hit paper breakdown → | 2020 | 649 |
About Ignacio Ivan Wistuba
Ignacio Ivan Wistuba is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology and Pathology and Forensic Medicine, having authored 803 papers that have together received 82.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (175 papers), Cancer Genomics and Diagnostics (123 papers), Cancer Immunotherapy and Biomarkers (85 papers), RNA modifications and cancer (68 papers), Lung Cancer Diagnosis and Treatment (64 papers), Lung Cancer Research Studies (61 papers), Cancer Cells and Metastasis (37 papers) and Genetic factors in colorectal cancer (37 papers). The work is most often cited by research in Oncology (31.2k citations), Cancer Research (16.6k citations), Pulmonary and Respiratory Medicine (27.3k citations), Immunology (8.7k citations) and Molecular Biology (27.4k citations). Ignacio Ivan Wistuba has collaborated with scholars based in United States, Netherlands and Japan. Frequent co-authors include Adi F. Gazdar, John Dorrance Minna, Carmen Behrens, Fred R. Hirsch, Keith M. Kerr, Ming‐Sound Tsao, Ximing Tang, Jaime Rodriguez‐Canales, Junya Fujimoto and Mary Beth Beasley. Their work appears in journals such as Journal of Thoracic Oncology, Clinical Cancer Research, Cancer Research, Annals of Oncology and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.